Komori
Changes in Officers4569KYORIN Pharmaceutical Co.,Ltd.Pharmaceuticals

Our Subsidiary: キョーリン製薬グループ工場株式会社 — Notice Regarding Changes in Officers

Okuzumi Ryota (奥積 亮太), a director of the Company's subsidiary, will retire from office effective 1 May 2026. No position after retirement or successor has been stated.

Worth reading
28Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Who is moving to which position

Departing officer

1 item
Date of departure1 May 2026
Okuzumi Ryota (奥積 亮太)Next role stated
Former PositionDirector, General Manager of the Business Administration Department, and responsible for the Production Control Division
New positionRetirement

“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.

Who is moving to which position
ItemDetails
Date of departure1 May 2026
Name of departing officerOkuzumi Ryota (奥積 亮太)
Former position of departing officerDirector, General Manager of the Business Administration Department, and responsible for the Production Control Division
New position of departing officerRetirement
Items this document does not state (17)
Resolution dateScheduled Appointment DateName of appointeeAppointee's new positionAppointee's previous positionAppointee's date of birthYear the appointee joined the CompanyNumber of shares held by the appointeeReason for departureWhether the incumbent will remain in officeReason for changeReasons for appointmentNumber of directors after the changeFiling as an independent officerDetails of organizational changesChange in Corporate Governance StructureSubject to Approval by the General Meeting of Shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

No reason for the retirement is stated.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Our Subsidiary: キョーリン製薬グループ工場株式会社 — Notice Regarding Changes in Officers | KYORIN Pharmaceutical Co.,Ltd. (4569) timely disclosure | Komori